SERACH RESULTS FOR" Development "
businessEthicBusiness Ethics BUSINESS PRINCIPLESSamsung's Management Philosophy is to "devote our human resources and technology to create superior products and services, thereby contributing to a better global society." Samsung's code of conduct is the foundation that allows us to create a fair, clean, and transparent corporate culture. BUSINESS ETHICS WEBSITE REPORTING WRONGFUL PRACTICES Samsung aims to be a 'world-leading company,' by devoting our human resources and technology to create best products and services, thereby contributing to a better society for all humans. To meet this goal, all Samsung employees share and pursue the Samsung Values of 「People, Excellence, Change, Integrity, Co-prosperity」. Furthermore, we have established and hereby declare to practice 「The Samsung Business Principles」 in a proactive manner in order to fully comply with all laws and ethical practices as well as to express our concrete commitment to our role and social responsibility as a corporate citizen. Laws And Ethics We comply with laws and ethical standards. 1-1 We respect dignity and diversity of individuals. The Company will respect the human rights of all employees.The Company will never allow forced labor, exploitation of wages and child slavery in any circumstances.The Company will not discriminate against stakeholders including customers and employees on the basis of national origin, race, gender, religion or any other characteristics protected by law. 1-2 We compete in accordance with laws and business ethics. The Company will accurately record and manage all transactions made so that all stakeholders can clearly understand our business activities.The Company will not obtain or gain illegally against business ethics.The Company will not permit the giving or acceptance of money, goods, entertainment or any economic benefits in doing business. 1-3 We maintain transparency of accounts with accurate recording of transactions. The Company will accurately record and manage all transactions made so that all stakeholders can clearly understand our business activities.The Company will comply with national and international accounting laws and regulations and internationally accepted accounting standards.The Company will disclose major business issues and corporate information such as change of financial status with due diligence in accordance with the law. 1-4 We do not get involved in politics and maintain neutrality. The Company will respect individual political rights and political opinions and at the same time not allow employees to perform any political activity within the organization.The Company's resources, including financial resources, manpower and facilities, shall not be used for political goals.The Company will refrain from illegal donations and any other giving of money for political reasons. Clean Organizational Culture We maintain a clean organizational culture. 2-1 We make a strict distinction between public and private affairs in our duties. When corporate interest comes into conflict with personal interest, the Company's legitimate interest shall come first.The Company shall not permit any illicit activity for the pursuit of personal gain, using one's position for private gain such as the embezzlement or misuse of corporate assets.Employees shall not conduct a transaction with marketable securities such as stock trading using the information acquired during the service of duties. 2-2 We protect and respect intellectual properties of the Company and others. Employees shall not leak corporate intellectual properties and confidential information without prior consent or approval to the outside.The Company will respect and not use, copy, distribute, or infringe on the intellectual properties of others in any other ways. 2-3 We create a sound organizational atmosphere. The Company has zero tolerance for any type of behavior that may hamper the relations between co-workers like sexual harassment, financial transactions and physical assaul
leadershipdevelopment through commercial supply stages. Furthermore, our experienced people provide expertise in cell line development, culture, purification, analytical testing, aseptic filling, and packaging. Our diverse capabilities, manufacturing scale, and flexibility represent a truly integrated one-stop service that meets all our clients’ needs. We will continue expanding our facilities and capabilities to meet growing market demand. As a global company, we pledge to continue Samsung’s legacy of excellence by combining our business, manufacturing, and engineering expertise, to bring innovation and progress to today’s biopharmaceutical industry. Sincerely yours, Dr. Tae Han KimPresident & CEO, Samsung BioLogics Key utives UTIVE VICE PRESIDENTKyusung Lee, Ph.D.Dr. Kyusung Lee is utive Vice President in charge of Contract Manufacturing Operation 1 of Samsung BioLogics. Prior to joining Samsung in 2010, Dr. Lee held various leadership positions in biopharmaceutical companies in the U.S. Dr. Lee began his career with Miller Brewing Company in 1991 as a biochemical engineer. He led the production team for Amoco BioProducts Corporation from 1992 to 1995 and was responsible for the technology transfer of a full scale biotechnology process, after which Dr. Lee moved to Merck & Co. During his tenure at Merck from 1995 to 2005, Dr. Lee participated in the design, construction, start-up, technology transfer, and commercial operation of biologics and pharmaceutical manufacturing facilities. From 2005 to 2010, Dr. Lee assumed responsibilities for technology transfer activities for Bristol-Myers Squibb Co.'s CMO programs. Dr. Lee holds a doctoral degree in chemical engineering from Purdue University. UTIVE VICE PRESIDENTJohn RimJohn Rim is utive Vice President in charge of Contract Manufacturing Operations 2 comprising the newest plant within Samsung BioLogics. Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with ALZA Corporation, a subsidiary of J & J, as a chemical engineer where he participated and led process and product development, technology transfer, validation and commercialization of several OROS products. He then worked in Technical & Alliance Management at Watson Pharmaceuticals. Transitioning to Merck as a Change Agent/Six Sigma Project Manager, Mr. Park then managed the Operational Excellence projects related to process improvements, cost savings and quality initiatives. From 2004 to 2015, Mr. Park participated in and directed 100+ CMC due diligences on assets ranging from pre-clinical to commercial products, and managed Global Manufacturing & Supply BD activities including Licensing, Outsourcing and M&A at Bristol-Myers Squibb. Mr. Park has over 25 years of experience in the biopharmaceutical and pharmaceutical industries. CFODongjoong KimDongjoong Kim is Senior Vice President and Managing Director in charge of the Business Resources Innovation Center which includes the Finance Team, Business Innovation Team, Corporate Information Technology Team, and Global Employee Satisfaction Team. Prior to joining Samsung BioLogics in 2014, Mr. Kim held various corporate planning and managerial leadership positions for Samsung Electronics. Mr. Kim began his career with Samsung in 1988. Mr. Kim led the Corporate Management and Administration of Samsung Electronics from 2002 to 2014. CBOJames ParkJames Park is Senior Vice President and Managing Director of the Global Business Development Center responsible for BD Operations Team, BD Innovation Team and Integration & Marketing Part of Samsung BioLogics. Prior to joining Samsung BioLogics in 2015, Mr. Park held various technical and operational positions, as well as business development management leadership positions in biopharmaceutical companies in the U.S. Mr. Park began his career in 1989 with
historyDevelopment Partnership with EutilexOCT. 2018 AEO CertificationOCT. 2018 Plant 3 cGMP ReadyJul. 2018 First DP Approval by FDAJul. 2018 Manufacturing Partnership with UCBJUN. 2018 Development Partnership with GI InnovationJUN. 2018 First Approval of Plant 1 by Health CanadaApl. 2018 ISO 22301 Certification (BCMS)DEC. 2017 First Approval of Plant 2 by EMANOV. 2017 Plant 3 Mechanical CompletionOCT. 2017 MOU for Strategic Alliance with MerckSEP. 2017 First Approval of Plant 2 by FDAJUL. 2017 Manufacturing Partnership with Sun PharmaMAY. 2017 First Approval of Plant 1 by PMDASamsung’s Innovative DesignPLANT 2 The Largest Single Plant5X Scale (DS 15,000L + DP Fill/Finish)Total Capacity - 152,000L (10x15,000L / 2x1,000L)Construction - 29 months to cGMP ready2016NOV. 2016 Samsung BioLogics IPO on KOSPINOV. 2016 First Approval of Plant 1 by EMAFED. 2016 Plant 2 DS cGMP ReadyNOV. 2015 First Approval of Plant 1 by FDANOV. 2015 Plant 3 Construction StartedOCT. 2015 Plant 1 PLI ApprovalFEB. 2015 Plant 2 mechanical CompletionAPR. 2014 Manufacturing Partnership with BMS2011-2013Standard DesignPLANT 1 Industry StandardIndustry Average Scale (DS 30,000L + DP Fill/Finish)Total Capacity - 30,000L (6x5,000L)Construction - 25 months to cGMP ready2013OCT. 2013 Manufacturing Partnership with RocheSEP. 2013 Plant 2 Construction StartedAug. 2013 Plant 1 DP cGMP ReadyJul. 2013 Manufacturing Partnership with BMS JUN. 2013 Plant 1 DS cGMP ReadyJUL. 2012 Plant 1 Mechanical CompletionMAY. 2011 Plant 1 Construction StartedAPR. 2011 Foundation of Samsung BioLogics
ResearchDEVELOPMENT Effective ProcessSamsung BioLogics develops both liquid and lyophilized drug products. We have an efficient platform process of formulation development based on Design of Experiment (DoE) approach, followed by stability test in long-term, accelerated and stressed conditions. This systematic platform process can help to save development time to IND. Formulation Development Liquid Formulation- Basic buffer & Excipient screening- DoE based Pre-formulation optimization- Nominal / Accelerated pre-stability test- Product impactassessment Lyophilization Development- Characterization of the freezing step- Lyophilized formulation development- Lyophilization cycle optimization- Manufacture of small scale batches Non-GMP Manual Filling- Aseptic manual filling for pre-clinical study- 2R-20R with flip-off al-cap crimping- Watson Marlow PF7 filling machine Other Activities1. Lyophilization Development- Characterization of the freezing step- Lyophilized formulation development- Lyophilization cycle optimization- Manufacture of small scale batches2. Non-GMP Manual Filling- Aseptic manual filling for pre-clinical study· 2R~20R with flip-off al-cap crimping· Watson marlow PF7 filling machine Equipment Capacity / DescriptionBio-safety Cabinet Formulation and other experiments preparationIncubator Stability storage during formulation screening (25C and 40C)Spectrophotometer Protein / DNA concentration analysisCentrifuge General analysisMicro-centrifuge General analysisDSC (MicroCal) Formulation stability simulationDLS (ZetaSizer) Confirm particle size distributionMFI Confirmation of aggregation in DS & DPLiquid Particle Counter (HIAC) Sub-visible particle measurementHPLC Target molecule identification (SEC, CEX, AEX) CRO SERVICESWe provide full CRO service including Contract QC (Release & Stability Testings) to support our client’s successful product launch in Korea BTS : Bio-safety Testing Service Mycoplasma Detection Testing- EP and USP Mycoplasma Culture Method Detection- JP Mycoplasma Culture Method Detection- EP Mycoplasma DNA Detection by PCR* Types of Mycoplasma : Mycoplasma hyorhinis, M. orale, M. fernentans, M.pnuemoniae, M. gallisepticum, Acholeplasma laidlawii Adventitious Virus Testing- In Vitro Assay for MRC-5, Vero and CHO-K1- In Vitro Co-culture / PG S+L- Focus Assay- Specific Virus DNA Limit Detection by qPCR* Types of Virus : Measeles virus, Parainfluenza virus 3, Parainfluenza virus 5, Munute virus of mice (MVM) Microbial Testing- Sterility Testing- Endotoxin Detection / LAL Test- Bioburden- Microbial identification Contract QC Service General Characteristics- Apperarance- Osmolality- pH- Sub-visible particles Chemical- A280- Peptide mapping- HPLC- N-glycan profiling Biological- Cell-based potency- ADCC- Antibody Proliferation Assay Biochemical- SDS-PAGE- iCIEF- DNA qPCR- CE- HCP ELISA
ManufacturingDevelopment Stage cGMP late clinical & commercial cGMP late clinical & commercial cGMP clinical cGMP late clinical & commercialPlant Specifications Shaker or Magnetic Stirring Flask CultureHybrid Depth Filtration System (POD, Typical Lenticular)Cultivation Type: Fed-BatchShaker or Magnetic Stirring Flask CultureLenticular Depth Filtration SystemCultivation Type: Fed-Batch- Shaker or Magnetic Stirring Flask CultureLenticular Depth Filtration SystemCultivation Type: Fed-Batch, PerfusionOperational Q3 2013 Q1 2016 2H 2016 Q4 2018Regulatory Compliance Global HA including FDA, EMA, PMDA, MFDS, Health Canada PURIFICATION Maximum Flexibility & Minimum Turnover Time Samsung BioLogics’ cGMP Drug Substance Downstream Purification consists of two facilities with the newest equipment for cGMP operations, including chromatography (e.g., affinity, ion-exchange, multi-modal), viral filtration, ultrafiltration/diafiltration (UF/DF), and formulation and bulk filling operations. Both facilities consist of physically segregated pre-viral and post-viral suites designed for maximum flexibility and minimum turnover time. Industry Leading Automation Solutions Each downstream facility can be adjusted to accommodate all customer process needs. All purification facilities are classified as Grade C or higher. The design minimizes opportunities for cross-contamination with physically segregated pre-viral and post-viral suites containing equipment dedicated to cleaning areas and a Grade B bulk fill room. Three separate column packing suites support optimization of production cadence. The high-capacity buffer preparation suites are designed for temperature control and contain hold tank sizes to handle buffer preparations up to 15,000 L. The downstream suites are equipped with chromatography skids, columns, UF/DF skids, virus filtration skids, and Grade A (laminar flow booth) bulk filling capacity as well as product pool vessel capacities from 200 L to 15,000 L to handle a wide range of pool volumes and high protein titers. Our purification process is supported by industry leading automation solutions. Specification Facility design based on gravity flowPlant dedicated utility committed to providing constant power supplyChromatography : Affinity, Ion Exchange, Hydrophobic, Multi-modal Columns range : 0.8m to 1.8m in diameter Automation controls integrated with MCS Columns to accommodate all range of sizesDedicated equipment for Pre-Viral and Post-Viral areas for cross-contamination control COP and glassware parts washers Autoclaves Utility station with CIP and SIP capabilities for portable equipment CIP and SIP capabilities for all production equipmentVF Operation : Fully automated Hybrid design to accommodate any configurationUFDF Operation : Fully automatedIn line and off line Recirc vessel capabilityBulk FillDedicated Grade B/A space Equipment/Capability division Plant 1 Plant 2 CMP Plant 3Type Mammalian Mammalian Mammalian MammalianEquipment Chromatography Skids, ColumnsUF/DF, VF SkidsProduct VesselsBuffer Prep. / Hold VesselsCIP SystemsSIP full capacityCOP/GWD Cabinets, AutoclavesChromatography Skids, ColumnsUF/DF, VF SkidsProduct VesselsBuffer Prep. / Hold VesselsCIP SystemsSIP full capacityCOP/GWD Cabinets, AutoclavesChromatography Skids, ColumnsHybrid UF/DF skidsSingle use VF skidProduct Pool ContainersBuffer Prep. / Hold ContainersAutoclavesGWDChromatography Skids, ColumnsUF/DF, VF SkidsProduct VesselsBuffer Prep. / Hold VesselsCIP SystemsSIP full capacityCOP/GWD Cabinets, AutoclavesCapacity/Capability Small to large scaleClosed samplingChemical additionsTemp control 2-37℃Class B/A Bulk FillPortable Equip stationsCryo Freezing Tank/Bag/BottleLarge ScaleClosed samplingChemical additionsTemp control 2-37℃Class B/A Bulk FillPortable Equip stationsCryo Freezing Tank/Bag/BottleChemical additionsTemp Control 2-37 ℃Class B/A Bulk Fill1 Purification SuitesLarge ScaleClosed samplingChemical additionsTemp control 2-37℃Class B/A Bulk FillPortable Equip statio
DevelopmentDevelopment Faster & BetterYOUR SUCCESS TO IND & BLA As your most qualified world’s leading CDMO partner, Samsung BioLogics delivers your success to IND & BLA Faster & Better with maximum flexibility. We promise the Best. From Gene to INDFrom Gene to IND1. Cell Line Development2. MCB Banking and Characterization3.Upstream Process DevelopmentDownstream Process DevelopmentFormulation DevelopmentAnalytical Method Development4.Non-GMP DS & DP ProdcutionNon-GMP DS & DP Stability Study5.cGMP DS ManufacturingcGMP DS Stability Study6.cGMP DP ManufacturingcGMP DP Stability Study7. IND Filing Support Timeline – Speed to IND Timeline of Cell Line development to DS productionYear Month Construction CLD to IND Filing : ~ 18 MonthCLD to DS Production : ~ 12 Month DS to IND Filing Semi-fast -2M Vector Construction -1M Year 1 1M Cell Line Development 2M 3M 4M Process Development- Upstream- Downstream- Formulation- Anaytical Method 5M 6M Non GMP DS (Tox.)- Non GMP DS Stability- Non GMP DP Stability- Interim Reference Stadard Qualification 7M 8M Analytical Method Transfer to QC 9M 10M Virus Clearance Study 11M cGMP Clinical DS- Lot Release- cGMP DS Stability 12M Year 2 13M GMP DS Characterization 14M 15M cGMP DP- Lot Release- cGMP DS Stability Regulatory Documentation16M 17M 18M CELL LINE DEVELOPMENT Right Start, and Better Quality At Samsung BioLogics, we provide high-quality mammalian cell line development for a variety of antibodies and proteins using the CHOZN platform. Along with Samsung BioLogics’ specialized cell line development know-how, our experts have extensive experience of molecule development including difficult-to-handle products and are capable of delivering robust, high-yield single cell clone to our clients. Cell Line Development Platform Process 1,2 : 1st screeing - Screen and rank potential clones into 5 pools3 : Single Cell Cloning - Support monoclonial process4 : 2nd screening - Screen and rank of top 10 subclones6 : Top 3 RCB - Screen and rank of top 10 subclones6 : Stability Study - Assess stable maintanance of titer and product qualtiy6.5 : Fed-Batch - Assess stable maintanance of titer and product qualtiy UPSTREAM PROCESS DEVELOPMENT Samsung BioLogics has a highly skillful development R&D team with dedicated focus on advanced development services. With our sophisticated platform development process, our team provides Process Development services utilizing Quality by Design (QbD) approach. Upstream Process Development Flow Molecule information / cell bank transferBasal Media Screening in shake flaskFeed Media Screening in shake flaskProcess Optimization In Ambr 15™Process verification run in 2L STR DOWNSTREAM PROCESS DEVELOPMENT Samsung BioLogics offers our established downstream process development platform developed by our highly experienced scientists. Together with our insights in bioprocess and manufacturing, we are capable of developing a customized, optimal and efficient process resulting in high yield manufacture in a timely manner. Downstream Process Development Flow Preparation for DSP Development Virus Inactivation Process Development Filter Preocess Development Process verification run in AKRA ANALYTICAL METHOD DEVELOPMENT Analytical Method Development Analytical Method Development - Quantity- Impurities- Identity- Potency- Glycan profile- Excipient- Purity & Heterogeneity Extended characterization & comparability studies - Primary strucure- High order structure- Biological activity Analytical Support - In-process analysis for USP and DSP development MANUFACTURING Small Scale Manufacturing – CMP 1 & CMP 2 As the world’s largest CDMO, we offer multiple cGMP manufacturing facilities to meet the diverse scales of our clients’ demands. Th
development, manufacturing, and research), making it easier to understand the company’s end-to-end business capabilities. Industry professionals and job seekers can also get an insight into the working environment and the numerous benefits offered at SBL, and interested candidates can submit their information to the SBL Talent Pool via the website. “For the past eight years, our company has been on a record-pacing journey of growth and innovation, and as our business capabilities and client services continues to evolve, it is crucial that our clients, prospective candidates, and anyone with a vested interest in Samsung BioLogics be able to quickly find the information they are seeking and understand our value proposition via our website. We are excited to announce that the launch of our new website was enabled by innovative information technology and interface design tailored to optimize end-user experience,” said a company representative.
development company with a high potential early stage asset with a requirement to ensure stable and consistent supply for its clinical trials and commercialization. Under the terms of the contract, the deal will increase to $39.8 million US when the client progresses development of the clinical product, and will increase to $301 million US when the client obtains approval for the product. The minimum committed amount can be additionally increased based on actual product demand. From the outset, Samsung BioLogics worked closely with the client in order to understand their needs. This allowed Samsung to come up with a flexible and client-centric deal that maximizes value creation for the client through multiple phases of clinical trials through to commercialization. The deal has been structured such that the client only has to make commitments for each individual clinical trial phase, thus minimizing the cash requirements for the client and protecting them from extensive financial liability in case the product does not advance to the next stage of development. The agreement also has automatic milestones that trigger as each clinical trial progresses successfully. If a trial has successful clinical results, the client automatically has access to production for the next clinical phase. When the final clinical trial concludes and the client’s product is approved by the health authority, the client automatically has access to a complete commercial agreement. This commercial agreement provides additional flexibility during the initial launch years to allow the client to adapt to varying demand until the market stabilizes, ensuring steady and high quality supply for each phase of development. “We believe we have entered a new era in Samsung BioLogics’ history with the creation of a new client-centric agreement that addresses the demand for not only variable and reliable supply through clinical trials but also for ensuring low COGS at the commercialization stage. This empowers our client with the ability to manufacture each phase of product at a different scale, increasing with each phase and allowing them to optimize their costs,” said Dr. Tae Han Kim, CEO of Samsung BioLogics. “This enables a small, early stage biopharma to have predictable, low-cost, and reliable supply of their product through every stage of development by signing one agreement. This is efficient not just from a supply and COGS perspective but also a resource perspective for a company that has limited human capital to deploy.” Samsung BioLogics expects this new type of innovative, client-centric agreement to be highly attractive to early stage companies by providing certainty of stable and reliable supply through various stages with optimized cost effectiveness at commercialization.
Development and other members of the Samsung BioLogics leadership team. "We are excited to work with Samsung BioLogics, one of the world's best CMO firms. Given the company has consistently demonstrated an extremely high level of quality assurance, capacity, and cost effectiveness, we expect that we will be able to market our new drug quickly following an expected approval," stated Nader Pourhassan, Ph.D, CytoDyn’s President, CEO and director. “It is important for our shareholders to realize that our partnership with Samsung is the first step in validating what we have accomplished and the future potential for leronlimab,” continued Dr. Pourhassan. “One of our major strategic challenges with leronlimab’s sales potential as a monotherapy (provided we obtain approval) was to ensure we have sufficient large scale biologics manufacturing capacity in place to meet the expected demand and our Samsung agreement now successfully satisfies this long-term strategic requirement,” concluded Dr. Pourhassan. “Samsung BioLogics is very excited to be partnering with CytoDyn to bring this potential blockbuster drug to the market. It is clear that leronlimab and the CytoDyn team have an opportunity to bring significantly improved care to HIV patients around the world. Samsung BioLogics is proud to support this effort by providing a stable supply of only the highest quality product,” said Dr. Tae Han Kim, CEO of Samsung BioLogics. Dr. Nader Pourhassan (Left), CEO of CytoDyn and Dr. Tae Han Kim, CEO of Samsung BioLogics The signing ceremony was capped by a tour of the Samsung BioLogics campus including the Plant 2 VIP showroom and a window tour of Plant 3, Samsung BioLogics’ latest state-of-the-art manufacturing facility optimized for high volume products such as leronlimab. About Leronlimab (PRO 140) The U.S. Food and Drug Administration (FDA) has granted a “Fast Track” designation to leronlimab as a combination therapy with HAART for HIV-infected patients and for metastatic triple-negative breast cancer. Leronlimab is an investigational humanized IgG4 mAb that blocks CCR5, a cellular receptor that appears to play multiple roles with implications in HIV infection, tumor metastases and immune signaling. Leronlimab has successfully completed nine Phase 1/2/3 clinical trials in over 700 people, including a successful pivotal Phase 3 trial in combination with standard anti-retroviral therapies in HIV-infected treatment-experienced patients. In the setting of HIV/AIDS, leronlimab belongs to a new class of therapeutics called viral-entry inhibitors; it masks CCR5, thus protecting healthy T cells from viral infection by blocking the predominant HIV (R5) subtype from entering those cells. Leronlimab has been the subject of nine clinical trials, each of which demonstrated that leronlimab can significantly reduce or control HIV viral load in humans. The leronlimab antibody appears to be a powerful antiviral agent leading to potentially fewer side effects and less frequent dosing requirements compared with daily drug therapies currently in use. In the setting of cancer, research has shown that CCR5 likely plays a central role in tumor invasion and metastasis and that increased CCR5 ex-pression is an indicator of disease status in several cancers. Moreover, research has shown that drugs that block CCR5 can block tumor metastases in laboratory and animal models of aggressive breast and prostate cancer. CytoDyn is conducting a Phase 2 human clinical trial in triple-negative breast cancer and was granted Fast Track designation in May 2019. Additional research is being conducted with leronlimab in the setting of cancer and NASH with plans to conduct additional clinical studies when appropriate. The CCR5 receptor also appears to play a central role in modulating immune cell trafficking to sites of inflammation and may be crucial for the development of acute graft-versus-host disease (GvHD) and other in
DevelopmentBusiness DevelopmentBD PlanningCorporate Business OperationPlanningProcurementLegal & CompliancePRCorporate managementFinanceInformation TechnologyHuman resources Application MethodComplete and submit application form to the e-mail address for recruitment at Samsung BioLogics. E-mail firstname.lastname@example.orgPassing of the application procedures and employment may be cancelled if the contents of the application form are found to be false. ※ Download Application Form REGISTER IN TALENT POOL Registered applications of candidates in talent pool are primarily reviewed for positions on demand.
DevelopmentBusiness DevelopmentBD PlanningCorporate Business OperationPlanningProcurementLegal & CompliancePRCorporate managementFinanceInformation TechnologyHuman resources Application MethodComplete and submit application form to the e-mail address for recruitment at Samsung BioLogics. E-mail email@example.comPassing of the application procedures and employment may be cancelled if the contents of the application form are found to be false. REGISTER IN TALENT POOL Registered applications of candidates in talent pool are primarily reviewed for positions on demand.
DEVELOPMENTSystematic training opportunities for the development of our employees’ values and competencies Values Develop Professional Competency to Lead the Bio-IndustryTo train the core values and unique culture of our company, we provide a range of educational courses for our employees. As a leading expert in the bio-industry, our employees can foster their ability for collaboration with collective intelligence and pride. Leadership Development of Leadership Capabilities for Mutual GrowthWe provide our employees with the opportunities to develop various leadership skills and abilities. Through these opportunities which include leadership training courses based on different levels and optimized courses for the role as a leader, effective communication skills and coaching abilities will be continually developed. Global Understanding Different Cultures and the Improvement of Communication SkillsWe provide an education program which broadens the understanding of different cultures through the development of communication skills that are an essential component. In-company language courses (including Korean courses for global employees) and Biz. Skill Up online courses support each employee as they seek to strengthen their ability to ute successful global businesses. Expertise A Compulsive Training Program for Professionalism DevelopmentWe provide a training program for our employees to improve expertise in OA, financial costs, and GMP that are vital requirements in the biopharmaceutical industry. In addition to that, in-company Biotech is supported for the purpose of training and the acquirement of technical knowledge.
Samsung BioLogics (hereinafter, the “Company”) values users’ personal information, complies with statutory obligation s on protection of personal information such as the Act on Promotion of Information and Communication Network Utilization and Information Protection, etc. and the Act on Protection of Personal Information, and has created a Policy to Handle (Process) Personal Information to protect the users’ right and interest to the maximum extent possible.
Through the Policy to Handle (Process) Personal Information, the Company publicizes its operations on personal information treatment (processing) with particulars such as the types of personal information collected from the users and the purpose of processing such information, the time limit for processing and holding in possession, users’ method to exercise their rights, measures to procure the security, and so on.
Whenever there is a change in the Policy to Handle (Process) Personal Information, including updating, deleting, or adding its contents, whether resulting from any amendment to the relevant statutory sources or the administrative policy or change in the Company’s internal policy, we will post the change on our website at www.samsungbiologics. com so as to keep the users updated.
The Company’s Policy to Handle (Proce ss) Personal Information contains the following:
The Company collects personal information for the following purposes. The pfi will not be used for any other purpose and whenever it is necessary to change the purpose, we will comply with the statutory requirements such as obtaining users’ consents in advance.
Review and reply to the inquiries from users
Check employment history, give notices for future recruitment opportunities.
|Required||Name, Email Address, Company, Occupation, Country, Areas of Interest|
|Optional||Job Title, Phone Number|
The following information may be generated and collected in the course of using the service.
Access long, cookie
Collection through Contact Us, Talent Pool within the Website
Collection through generated information collection tool (for access long, cookie, etc.)
Personal information that needs to be collected and utilized inevitably as specifically required by law or regulations, or in order to comply with statutory requirements : As long as it is necessary to keep such information in possession under relevant statute.
Personal information that needs to be collected and utilized inevitably in order to execute and perform various contracts: Until the purpose of collection/utilization is accomplished.
Personal information collected and used with the consent of individual user: For the time period consented to.
If the user has given his/her consent in advance.
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements, or if it is deemed necessary for the sake of life, body or property of the information owner or a third party when the information owner or his/her legal representative is under a state incapable of communication or unable to give consent due to unknown domiciles or otherwise (only to the extent the purpose of collecting personal information is served).
User’s personal information
History of the users personal information being utilized or provided to a third party
History of consents given to collection, utilization and provision of personal information
If it is specifically required by laws or regulations or inevitable in order to comply with statutory requirements.
If it is likely to jeopardize a person’s life or body or unjustly infringe a person’s property or other interests.
The Company is operating cookies that regularly stores and locates users’ information.
How to install cookies (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, users may set the level of allowing cookies as suitable for their own needs.
How to view the cookie received (if using Internet explorer 8.0)
Select “Internet Option” in the “Tool”. Click “General” tab and select “Setting” of the Browsing History to check the files in “View Files”.
How to disallow cookie installation (if using Internet explorer 8.0) Select “Internet Option” in the “Tool”. Click “Privacy” tab. Using “Setting”, set it to the higher level, that is, “Block All Cookies”
in handling users’personal information, the Company endeavors to keep the personal information from being lost, stolen, revealed, tampered or damaged. To this end, the following technical and managerial actions are taken.
The Company implements its own internal management plan to secure safety in processing the personal information.
The Company is operating an internal organization dedicated to personal information protection to monitor the status of compliance with the personal information protective requirements and the responsible staff’s duty performance and takes corrective measures when any irregularity is found.
Installation and operation of access restriction device Using the intrusion blocking system, the Company controls any unauthorized access from outside and endeavors to procure all the technological system to the maximum extent feasible in order to secure systematic security.
Minimized designation of personal information processors and education The Company minimizes designation of personal information processors and implements internal and/or outsourced education on a regular basis. Personal information processors’ duty handover is conducted with the security fully maintained and their responsibilities for any personal information accident are clearly defined even after they have left the Company.
Restrictions on access to personal information The Company places restrictions on access to personal information through granting, changing or revoking the right to access to database system that processes personal information. We also record the history of granting, changing or revoking the right, which are retained for our records for at least three years.
The personal information of users is protected by the password and the file and transmission data are encrypted or stored by using file lock function. More important data are protected through certain separate security measures.
The Company has adopted security devices that enable safe transmission of personal information on the network using encryption algorithm.
To safeguard personal information from leak or loss by hackers or computer viruses, the Company has installed a security program and conducts periodic updating and reviewing.
For unmistakable security operation, every server is installed with intrusion blocking system as a means to block outsider intrusion by hacking as well as a system to analyze vulnerability.
To protect users’personal information and handle personal information-related customer complaint, the Company has appointed a personal information manager and processor. Any inquiry related to personal information protection and management should be directed to the personal information processor for instant and adequate reply.
Division: General Affairs Security Part, Personnel Management Team
Any user seeking to relief from personal information infringement may apply for resolution or consultation to Personal Information Dispute Mediation Committee, Korea Internet and Security Agency (Personal Information Grievance Center). In addition, users may contact the following institutions to be consulted on personal information infringement cases.
Personal Information Dispute Mediation Committee (118)
Korea Internet and Security Agency (Personal Information Grievance Center)(www.kopico.or.kr/1336)
Information Protection Mark Verification Committee (http://eprivacy.or.kr/02-580-0533~4)
Internet Crime Investigation Center of the Supreme Prosecutors’ Office
Cyber Police Agency (www.police.go.kr/1566-0112)
Personal information Protection Committee (http://privacy.kisa.or.kr/kor/main.jsp)/02-2180-3000)
When this ‘Policy to Handle (Process) Personal Information’ needs to be changed to reflect the change in statutory sources or government policies, we will put such change in public notice through an advisory statement and a separate window on the website.
Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.